Furthermore, the age-related suppressive status of elderly TDLN CD11c+ cells and T cells was exacerbated during IL-2/CD40 immunotherapy, which may have contributed to its reduced efficacy in elderly mice with mesothelioma. This evidence concerns the gene CD40 and mesothelioma.